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What causes non-adherence among some 
individuals on long term antiretroviral therapy? 
Experiences of individuals with poor viral 
suppression in Uganda
Dominic Bukenya1*, Billy Nsubuga Mayanja1, Sarah Nakamanya1, Richard Muhumuza1 and Janet Seeley1,2
Abstract 
Background: Antiretroviral therapy (ART) use by people living with HIV reduces HIV transmission, morbidity, mortal-
ity, and improves quality of life. Good ART adherence is required to achieve these benefits. We investigated how the 
environmental, social, economic and behavioural experiences of people living with HIV with poor viral suppression 
could explain their non-adherence to long term ART.
Methods: This qualitative cross-sectional study was conducted in Uganda between September 2015 and April 2016. 
Thirty individuals on ART for 5 years or more (10 on first line and 20 on second line), with poor viral suppression, 
were randomly selected from a cohort of people living with HIV on ART. In-depth interviews about ART; awareness, 
adherence counselling, obstacles to daily adherence and regimen switches were conducted. Emerging themes from 
the interviews transcripts and field notes were identified and thematic content analysis done. Participants’ consent, 
compensation, confidentiality and study ethical approvals were ensured.
Results: We found that poor adherence to long term ART was due to: travel for work or social activities, stigma, 
receiving little or no continuous ART adherence education, alcohol consumption and use of alternative ‘HIV cure’ 
medicines. Other reasons included; ART side effects, treatment fatigue, belief that long-term ART or God can ‘cure HIV’, 
and food security.
Conclusions: Achieving optimal ART benefits requires continuous provision of ART adherence education to individu-
als on long term ART. This helps them overcome the challenges related to living with HIV: worries of food insecurity, 
alcohol misuse, economic hardship, and beliefs in HIV cures and use of unproven alternative HIV treatments. People 
living with HIV who travel require adherence support and larger quantities of ART refills to cover their time away.
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Introduction
Antiretroviral therapy (ART) use in HIV management 
has reduced morbidity and mortality among people living 
with HIV. ART also improves life expectancy and quality 
of life for people living with HIV, while the resultant viral 
suppression reduces the HIV transmission risk [1–5]. 
Good adherence, defined as following the recommenda-
tions made by the treatment provider on timing, dosage 
and frequency of medication taking [6], is a prerequisite 
to realising these ART benefits [7–12]. However, adher-
ence remains a challenge for many people living with 
HIV [1, 13–15].
A systematic review of individual and contextual factors 
affecting retention and adherence among pregnant and 
post-partum women living with HIV found that religious 
beliefs and use of alternative medicines discouraged ART 
adherence [16]. Similar findings have been reported from 
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other studies involving different populations [17–19]. 
Other systematic reviews of barriers to ART adherence in 
developing and developed countries showed that the fear 
to disclose HIV status, treatment suspicion together with 
the desire to avoid taking medication in public places 
among others, negatively affected adherence [20, 21]. In 
Botswana, 31% of the patients on ART found it hard to 
cope with a long duration on ART due to: financial dif-
ficulties, forgetfulness, travel, side effects and being food 
insecure [13]. Similar findings have also been reported in 
Democratic Republic of Congo, Zambia, Uganda, Kenya 
and Tanzania [22–27]. There are contrasting reports on 
the association between duration on ART and adher-
ence. Whereas some studies have reported decreasing 
adherence with increasing duration on ART [2, 14, 17, 21, 
28–31], others have reported an increase in adherence as 
people stay longer on ART [29, 32–36].
Despite the available evidence, few studies have exam-
ined the underlying environmental, social, economic and 
behavioural circumstances among people living with HIV 
with poor viral suppression that could explain their non-
adherence to ART. In addition, to achieve the UNAIDS 
2020 targets (90% of all people living with HIV will know 
their HIV status, 90% of those people will be on ART and 
90% of them will be virally suppressed [37]), issues of liv-
ing with HIV and long term ART use to ensure viral sup-
pression need to be explored further [38]. In this paper 
we examine the experiences of people living with HIV 
with poor viral suppression and how different circum-
stances could explain their non-adherence to long term 
ART.
Methods
Study design and settings
This cross sectional qualitative study was nested in the 
Complications of Long-term Antiretroviral Therapy 
(CoLTART) cohort study that was conducted in Kalungu 
and Wakiso districts in Uganda. The CoLTART cohort 
was a 3 year cohort established in 2013 to study the long-
term clinical and virological consequences of ART and 
HIV among African patients [39]. In Kalungu district, the 
CoLTART participants were recruited from the former 
Rural Clinical Cohort (RCC) in Kyamulibwa, where ART 
was introduced in 2004 [40]. In Wakiso district, the CoL-
TART participants were recruited from the Entebbe site 
of the former Development of Antiretroviral Therapy in 
Africa (DART) Trial, where ART has been provided since 
2003 [41]. The CoLTART cohort study ART clinics were 
well equipped and staffed. In addition, HIV care medi-
cations including ART and cotrimoxazole were always 
in stock and people living with HIV were offered ART 
adherence health education. During the pre-ART ini-
tiation health education sessions, participants and their 
treatment supporters were prepared for ART initiation 
[42]. Continuous post ART initiation health education 
was offered to people living with HIV at every ART refill 
visit to encourage them  to adopt safe sexual behaviours 
and adherence to ART. The CoLTART cohort therefore 
provided us with a platform to investigate the underly-
ing environmental, social, economic and behavioural cir-
cumstances contributing to non-adherence to long term 
ART. Long term ART in this paper is defined as being on 
ART for 5 years and above.
Study population and sampling
At enrolment into CoLTART, 110 (12.5%) of the partici-
pants had viral loads ≥ 1000 copies/ml, 74 (67.3%) were 
on first line ART and 36 (32.7%) on second line ART 
[43]. A random stratified sampling technique was used 
to select 30 participants who had been on ART for 5 
or more years. We aimed for more participants (20) on 
second line ART than on first line ART (10) due to their 
limited treatment options in Uganda where third line 
ART is not readily available. All the selected participants’ 
plasma viral load was greater or equal to 1000 copies/ml 
and were evenly distributed between the two CoLTART 
cohort study sites.
Data collection and management
In-depth interviews were used to collect qualitative 
data from September 2015 to April 2016. A male and a 
female, experienced, local interviewers conducted the 
interviews which were audio recorded, but the interview-
ers also wrote field notes. The interviews lasted between 
an hour to an hour and a half and were conducted in 
Luganda, a widely spoken and understood language in 
the study area. The interview guide included topics about 
ART awareness, pre-ART and post-ART initiation adher-
ence counselling, obstacles to daily ART adherence and 
circumstances leading to switch of regimen for those on 
second line ART.
Interviewers developed detailed interview accounts in 
English of each interview using both the audio record-
ings and the field notes soon after collection. Interview 
accounts were prioritised over interview transcripts 
because they provided additional information about the 
circumstances of data collection beyond transcribed 
recordings. The two interviewers were experienced in 
this approach and wrote detailed interview accounts 
which they shared to check clarity and completeness 
to ensure minimal errors and consistency. Thereafter, 
the study co-principal Investigator read each interview 
account and provided feedback to the interviewers while 
the principal investigator read a sample of these. The 
interviewers provided the additional information by lis-
tening to the audio recording again and/or re-reading 
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through the field notes. The final interview accounts were 
kept on password protected computers during analysis 
and stored on a secure server, where access was restricted 
to the study team.
Data analysis
The final interview accounts were read to identify emerg-
ing themes, which were discussed and a final coding 
framework was agreed on. The first coding level involved 
manual coding for circumstances leading to non-adher-
ence to long term ART. The second level of coding was to 
identify the patterns of these long-term ART non-adher-
ence circumstances and their main drivers. This coding 
level also involved extraction of illustrative quotes from 
the interviews presented in this paper.
Ethics approval and consent to participate 
and for publication
The Uganda Virus Research Institute Research and Ethics 
Committee and the Uganda National Council for Science 
and Technology approved this study.
Prior to the interview, signed written informed consent 
was obtained. In case of non-literate participants, a wit-
nessed thumb-printed informed consent was obtained. 
Consent was provided for participation and for publica-
tion, including giving consent to the following statement: 
‘I agree that anonymised direct quotes from the ART 
adherence interview may be used in the public reporting 
of these interviews’. Study participants were compensated 
for their time and they were assured of confidentiality.
Results
Of the 1095 individuals enrolled into the CoLTART 
cohort, 220 (20.1%) were on the second line ART, 110 
(10.5%) had HIV RNA viral load of 1000 copies/ml or 
higher, including 36 on second line ART, as noted above. 
Between September 2015 and April 2016, in-depth inter-
views were held with 30 participants (10 on first line and 
20 on second line ART); mean age 41.7  years (standard 
deviation 8.7), 18 (60%) females and about 80% were 
Christians. Almost half (47%) of the participants were 
either married or in a relationship,  and a third were 
either separated or divorced. Half was educated up to pri-
mary level.
Working away from home and work‑related mobility
Sixteen of the thirty respondents reported that work and 
social related travel affected their adherence to ART. 
Some, especially men (7/12), explained that they often 
worked and spent long periods away from their homes 
and occasionally carried fewer ART tablets than they 
needed or feared the stigma of being seen taking daily 
medications as this would raise suspicion of one being 
HIV infected. Others missed refill appointments either 
because of work commitment or failure to raise trans-
port fares or both. Three men reported that their ART 
drugs were finished while working in Juba, South Sudan. 
When they came back for refills, their ART regimen was 
switched after the health workers had rebuked them for 
failing to take ART. Only a few of the women (4/18), 
mainly urban, who worked in bars, shops or operated 
small restaurants reported being non-adherent to ART 
because they either worked far away from their homes or 
they finished the days’ work late and could not take their 
ART medication at their work places.
“There are times when I swallow late particularly 
when I have many customers. I fear to swallow in the 
presence of other people”, female aged 23  years, on 
first line ART.
Both men and women attributed the failure to take 
daily ART dose at the work place to being busy, fearful 
of anticipated stigma and or raising suspicion of HIV 
infection.
“At times you get trips to travel, like travelling to 
Juba (South Sudan) for work and drugs get finished 
yet coming back is hard. This also contributes to my 
non-adherence to treatment”, male aged 44 years, on 
second line ART.
“Sometimes, I don’t have anything to eat especially 
in the morning. I attend high profile meetings and 
during these meetings we are not allowed to move 
out. During these meetings, they serve biscuits, yet I 
am diabetic I can’t take that”, male aged 51 years, on 
first line ART.
“There are times when I take the morning dose and 
fail to swallow the evening dose particularly when 
I’ve travelled far away from home. I am a taxi 
motorcyclist and get home late”, male aged 33 years, 
on second line ART.
In addition, some female participants (5/18) who 
reported non-adherence to ART after several years on 
treatment, attributed their difficulties with taking their 
drugs to their travels to care for sick relatives and or 
attending funeral or wedding ceremonies. They explained 
that sometimes they would end up staying longer than 
the drugs they had carried and yet they could not raise 
the transport fares back to their ART clinics. Four 
women on second line ART regimen reported that they 
had moved away for a period of 1 or more months and 
during this time they did not take any ART medicines. 
When they returned, the health workers rebuked them 
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for failing to take their drugs and ran tests to find out 
whether the ART was still effective and subsequently, two 
of them had their ART regimen switched.
“I am involved in business and work in markets. I 
carry drugs for two months thinking I would be back 
then but I end up spending three months”, female 
aged 28 years, on second line ART.
“When I come to the shop without my drugs hoping 
to go back before the time for my drugs, sometimes I 
end up staying 3–4 extra hours. Yet the counsellor 
warned us during the pre-ART initiation adherence 
counselling not to take the tablets (ART) after delay-
ing beyond 2 h”, female aged 40 years, on second line 
ART.
Relaxed continuous ART adherence education/counselling
Even though continuous ART adherence education was 
to be offered at every ART refill visit, this was not always 
the case. About a third (9/30) of the participants reported 
missing taking their ART medications sometimes. They 
reported that when they came for ART refills, they were 
simply asked whether they were still adherent and how 
they were doing. They also explained that the continuous 
ART adherence education was only offered to those who 
were suspected to be non-adherent based on stagnant or 
decreasing CD4 cell counts.
“They no longer offer adherence health education 
and I also relaxed in taking my medication (ART). 
I think they think we are now well versed”, male aged 
54 years, on first line ART.
“They just ask if you are taking your drugs well and 
then they give you the drugs. They don’t repeat the 
ART adherence health education messages. I think 
they know that you understood clearly what to do 
but with ART you need to be motivated to continue 
taking it daily”, female aged 28 years, on second line 
ART.
Alcohol use or misuse
Most respondents (9/12) reported alcohol use, regardless 
of the ART regimen line they were on, however only two 
reported skipping taking their medication due to alcohol 
use. They argued that in the pre-ART and post-ART ini-
tiation adherence education sessions, they were asked to 
reduce alcohol use not to cease its use completely.
“Sometimes, I take alcohol excessively and not only 
forget to take food but also drugs. The health care 
workers even switched my drugs to the type I am tak-
ing now. I still struggle to take the tablets”, male aged 
37 years, on second line ART.
In contrast, no female respondents reported using alco-
hol. The women reported that although they took alcohol 
prior to ART initiation, they stopped it completely when 
told to do so by the counsellors.
“I stopped taking alcohol completely shortly before 
I was put (initiated) on these HIV drugs (ART). The 
counsellor told us that the drugs were incompatible 
with alcohol and that one had to choose between 
drugs and alcohol. That is when I chose drugs and 
gave up on alcohol. I have never tried it again”, 
female aged 32 year old, on first line ART.
Availability of other HIV treatment options
Eight respondents, mostly females (5/8) reported that 
their adherence to long term ART was sometimes inter-
rupted because of the use of alternative medicine options. 
They explained that there were radio advertisements of 
alternative medicines which reportedly cure all illnesses 
and told them that taking too much western medication 
was dangerous to their health.
“I am asthmatic and I sought herbal medicines for 
this at one time. When I reached they checked using 
the palms of their hands. After checking they told 
me that I had pressure too. I was given drugs/herbs 
in tea leaves form and they told me it cures all ill-
nesses. During the time I took this herb, I ceased tak-
ing the tablets (ART)”, female aged 53 years on sec-
ond line ART.
Treatment fatigue
Seven respondents reported that their non-adherence to 
ART was out of “obutaffaayo” (laziness) or simply being 
tired of taking ART endlessly. Such participants accorded 
themselves drug holidays. For some this behaviour con-
tributed to becoming non-adherent.
“I swallowed at the beginning but when I became 
stronger, I stopped taking. I could not swallow as I 
was supposed to”, male aged 42 years, on second line 
ART.
It was apparent that for some study participants 
‘becoming tired of ART’ was a proxy for other barriers to 
adherence, such as stigma or fears about side effects.
Experiences or fear of ART side effects
Six respondents, two on first and four on the second line 
ART regimen, reported that experiences or fear of treat-
ment side effects led to their non-adherence to ART. 
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They explained that although during the pre-ART initia-
tion health education, the health workers informed them 
that the side effects would be mild, some of them (3/6) 
had experienced very severe side effects. The severity of 
the ART side effects compelled these participants to dis-
continue ART to get relief. Among the reported severe 
side effects were: body deformities, severe headaches, 
nausea, numbness, diarrhoea and skin rashes.
“The drugs used to give me problems, so they 
changed them. Even now, it still gives me black swol-
len patches on the skin, I vomit the food I have eaten. 
For this reason, sometimes I don’t take the medica-
tion”, male aged 28 years, on second line ART.
“I sometimes don’t take my medicine when I am 
leaving home. The medicine makes me feel bad and 
I fear collapsing in the public because I work in the 
market”, female aged 37 years, on second line ART.
In addition, four respondents who had not experienced 
any ART side effects, sometimes also missed taking their 
ART and/or tuberculosis medication because they feared 
the possibility that side effects may occur. They reported 
that they had heard about the ART side effects from 
friends who had such experiences, the ART adherence 
education sessions from health workers and from radio 
programmes. Irrespective of ART regimen line, these 
participants’ fears resulted in three of them completely 
discontinuing ART.
Belief that God or ART can cure HIV
Five of the 18 female respondents reported ceasing taking 
ART because they believed that either God or ART drugs 
had cured their HIV infection. Three female Pentecostal 
Christians reported that they had been cured by God, 
and therefore had no need to continue taking ART. They 
also added that their pastors asked them to stop taking 
ART drugs.
“I stopped taking the drugs because I believed that 
God had cured my HIV infection”, female aged 
33 years, on first line ART.
Others said that they believed and felt cured of HIV 
infection after being on ART for years since they no 
longer had any illnesses and carried out their daily activi-
ties without any hindrances which was proof that the 
ART had cured the HIV infection.
“I believe that when you adhere to the medication 
and you resist from all worldly doings, these drugs 
reach a time and they cure the HIV completely”, 
female aged 44 years, on first line ART.
These two women alleged that they were never told the 
truth during ART adherence education sessions when 
they were told that ‘ART did not cure HIV infection’.
“if you faithfully follow the doctor’s instructions 
about taking the tablets (ART), they (ART tablets) 
make the (HIV) virus so weak to the point of curing 
it completely”, female aged 37 years on first line ART.
Food insecurity
Four of the 15 urban respondents reported skipping 
taking their ART medicines because they did not have 
anything to eat prior to or soon after taking their medica-
tions. This was not mentioned by the rural respondents. 
The urban participants had become food insecure follow-
ing job losses. They explained that sometimes they got 
food to prepare several hours past the time of taking the 
day’s ART dose yet during their ART adherence educa-
tion sessions, they are cautioned against taking medica-
tions on an empty stomach. They added that every time 
they took ART drugs on an empty stomach, they experi-
enced side effects. A combination of food insecurity lead-
ing to variations in meal time and fear and/or experience 
of drug side effects led to non-adherence to ART in the 
long run.
“I take when I have food and when I have no food I 
stop taking the drugs”, male aged 42 years, on second 
line ART.
I sometimes lack food as a result I fail to take medi-
cation in fear of medicine affecting me badly”, female 
aged 43 years, on first line ART.
Incarceration
Three of the 12 male respondents reported that they fre-
quently got imprisoned which affected their adherence to 
ART medications. They explained that while in prison, they 
sometimes missed taking their ART drugs. This was partly 
due to lack of food/water with which to take their drugs and 
being incarcerated at far away facilities from their ART refill 
clinics. They reported that prison authorities only served 
two meals a day: at mid-morning and early evening hours, 
times that were not compatible with their ART taking time 
and resulted in non-adherence to ART medications.
“When you are in prison, they can’t give you water 
and food to take your medicine every day. I am often 
taken to prison because of a land wrangle with my 
neighbour. Whenever, I am in prison, I miss taking 
my drugs (ART)”, male aged 44 years, on second line 
ART.
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Discussion
In this cross-sectional qualitative study among Ugandan 
adults on ART for 5  years or more but with poor viral 
suppression, majority of the respondents attributed their 
poor adherence to: working away from home, stigma 
and non-HIV serostatus disclosure, relaxed continuous 
ART adherence education/counselling and alcohol use 
or misuse. In addition, a few others attributed their poor 
adherence to availability of other HIV treatment options, 
treatment fatigue, experiences or fear of ART side effects, 
belief that God and ART can cure HIV, food insecurity 
and incarceration.
We found that as people’s health improved on ART, 
some individuals move to places far from their ART refill 
clinics in pursuit of work to earn an income resulting into 
missing ART refill appointments. The missed ART refill 
appointments could be due to either busy work sched-
ules, lack of transport fares or could even have been 
used to mask either perceived or experienced stigma 
[44]. These challenges are likely to affect more people, 
as increasing numbers are diagnosed as living with HIV 
as universal treatment access is rolled out in the effort to 
reach the UNAIDS 2020 targets [45].
Resuming work could be an indicator of the normalisa-
tion process which is a shift from the diseased to healthy/
normal self-identity. An ‘HIV-diseased identity’ is charac-
terised by consistent routine drugs taking, dos and don’ts 
some of which could result into involuntary HIV serosta-
tus disclosure. To avoid this and the resultant stigma 
either experienced or imagined, some patients could 
decide to find work at faraway places resulting in non-
adherence to long term ART. Studies elsewhere found 
that longer duration on ART together with poor health 
care workers’ communication were significant predictors 
of non-adherence [24, 46–50]. The solution to this lies in 
consistent continuous health education and addressing 
the challenges of providing an ART delivery model where 
stable ART patients can get larger ART refill quantities or 
allowed to refill from any nearby ART delivering clinic.
A longer duration on ART can improve people’s health 
and also promote changes in perceived stigma [51]. Due 
to high self-stigma levels, individuals who worked away 
from their homes feared to be seen taking their pills at 
their work places by claiming to be very busy. Similar 
findings were reported from studies done in Botswana, 
Ethiopia, Kenya and Nigeria, but among individuals on 
ART for less than 5 years. In these studies, it was found 
that non-adherent ART patients attributed non-adher-
ence to feeling healthy, being too busy to interrupt work 
schedules and stigma [52–55].
Providing continued ART adherence education 
remains an important challenge to long term ART adher-
ence in developing countries faced with a high HIV 
burden. These countries have low staffing levels amidst 
an ever-increasing number of patients on ART. With the 
increasing number of patients on ART, health care work-
ers need to prioritise the new patients recently initiated 
on ART, and this challenge will increase as more people 
living with HIV take ART [46, 56–58]. Not reinforcing 
messages or sharing new information about ART could 
affect adherence as suggested by some of our respond-
ents, a finding corroborated by a study from Lesotho 
where people living with HIV who were stable on ART 
were receiving fewer adherence education sessions, con-
tributing to non-adherence. However, these people living 
with HIV had been exposed to ART for less than 5 years 
[54].
The finding that alcohol misuse led to non-adherence 
to long term ART especially among men is consistent 
with studies from Uganda, Zambia, and Democratic 
Republic of Congo that reported that as health improved, 
people resumed alcohol use [29, 52, 54, 59]. A systematic 
review and meta-analysis of studies conducted in Ethio-
pia also reported that alcohol use was among the risk fac-
tors for ART non adherence [60].
The beliefs in available “alternative HIV treatment 
options” which we observed in our study was also shown 
in research in Ethiopia which reported that periodic reli-
gious rituals were barriers to ART adherence whether in 
the short, medium or long term perspective [61]. Tradi-
tional healers have also been reported to promote ART 
non-adherence although the majority of the participants 
in these studies had been on ART for durations shorter 
than 5 years [23, 25, 54, 62, 63].
We also found that fear and/or experience of ART side 
effects led to non-adherence to long term ART. Other 
studies have reported similar findings especially among 
food insecure patients [23, 48, 49, 54, 55, 62] though 
almost all these studies did not include people on ART 
for long durations who were experiencing poor viral 
suppression.
Beliefs that God and ART can cure HIV have been 
reported in an African and Asian cohorts comparative 
analysis [21]. Research in Ethiopia reported that some 
ART patients skipped their daily doses due to religious 
ritual observance, but also because of a belief that that 
God had cured them of HIV [18, 61, 64]. Contrary to 
these findings, a study in Uganda found that being reli-
gious facilitated long term ART adherence [58].
In our study, food insecurity was reported to contrib-
ute to non-adherence to long term ART only among the 
urban residents. Studies in other resource limited set-
tings in the Democratic Republic of Congo, Namibia, 
Kenya’s capital city Nairobi and resource rich Atlanta in 
USA have also reported that food insecurity was com-
mon among the poorest people living with HIV and an 
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important barrier to ART adherence [23, 28, 47, 48, 62], 
underlining the importance of livelihood enhancement 
and general development in supporting people living 
with HIV [49, 53].
Conclusion
Although we did not aim to generalise our findings to 
other populations, our study provides insights relevant 
beyond our study population of individuals on long 
term ART with poor viral suppression because people 
living with HIV and on ART can easily move in and 
out of adherence/non-adherence categorisation. Also 
regardless of the adherence category one takes up, all 
people living with HIV and on ART are faced with daily 
demands of ensuring continued adherence. To achieve 
optimal benefits from ART, health workers should 
continue providing ART adherence education to indi-
viduals on long term ART who are vulnerable to chal-
lenges of the normalisation process like resuming work 
activities, stigma re-emergency and treatment fatigue 
among others. These challenges are bound to become 
more prevalent in view of the UNAIDS 2020 targets. 
Individuals who work far from their homes and ART 
clinics could have refills of larger quantities than usu-
ally dispensed or considered for temporary transfers 
arrangements to ART clinics near their places of work. 
In addition, embedding economic empowerment and 
managing alcohol abuse among individuals on long 
term ART would go a long way to ensure ART adher-
ence. Efforts geared towards improving access to HIV 
diagnosis, linkage to care, ART initiation, retention and 
adherence call for more investment in the health sector 
performance monitoring.
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